# Zinc Finger Protein-Based Prognostic Signature Predicts Survival in Lung Adenocarcinoma

## TL;DR

This study identifies a 21-gene signature of zinc finger proteins that predicts survival in lung adenocarcinoma patients, offering a new tool for personalized cancer care.

## Contribution

A novel ZNF-based prognostic model is developed and validated for predicting LUAD patient survival.

## Key findings

- A 21-ZNF signature stratifies LUAD patients into distinct risk groups with differing survival outcomes.
- Eight core ZNFs show consistent dysregulation in both cell models and clinical datasets.
- Low-risk patients exhibit significantly prolonged survival compared to high-risk patients.

## Abstract

Zinc finger proteins (ZNFs) are crucial transcriptional regulators in cancer progression, yet their functional roles in lung adenocarcinoma (LUAD) pathogenesis require systematic characterization. This study aimed to develop a ZNF-based prognostic model for LUAD outcome prediction. Transcriptomic data from TCGA were analyzed via univariate Cox and LASSO regression to construct a risk score model. External validation used GEO dataset GSE68465 with identical protocols. Multivariable Cox regression controlled confounders. Experimental validation included: (1) ZNF expression profiling in LUAD/normal cells; (2) qRT-PCR technical verification. Key Results: 1. A 21-ZNF signature stratifies LUAD patients into distinct risk cohorts. 2. Low-risk patients exhibit significantly prolonged survival. 3. Eight core ZNFs (|coef| > 0.1) show consistent dysregulation in cell models and clinical datasets. The ZNF-derived prognostic framework provides a clinically applicable biomarker for LUAD survival prediction. Its integration into precision oncology may accelerate therapeutic target discovery, ultimately improving patient outcomes through personalized risk management.

Background: Zinc finger proteins (ZNFs), functioning as pervasive transcriptional modulators, serve as pivotal mediators of tumorigenesis and malignant advancement. However, the mechanistic contributions of these epigenetic orchestrators to lung adenocarcinoma pathogenesis remain incompletely characterized. Methods: To elucidate zinc finger proteins’ biological significance in lung adenocarcinoma (LUAD) pathogenesis, we first extracted relevant transcriptional data from TCGA. After preliminary screening with univariate Cox regression, a LASSO algorithm was applied to optimize the risk score model, incorporating key zinc finger protein markers. For independent validation, we accessed GEO dataset GSE68465, applying identical analytical protocols to confirm model generalizability. We performed multivariable Cox regression to identify independent predictors of clinical outcomes after adjusting for confounding variables. Cell-based validation included (1) comparative analysis of zinc finger protein expression across LUAD/normal cell models and (2) technical verification using standardized qRT-PCR protocols. Results: Following rigorous bioinformatics screening comprising differential expression and survival analysis, the final 21-zinc finger protein cohort was selected for risk score algorithm development aimed at clinical outcome prediction. Stratification based on computed risk scores revealed markedly superior survival outcomes in the low-risk cohort compared to high-risk patients. Comparative analysis revealed overall concordance in the transcriptional profiles of eight ZNFs (|coef| > 0.1) across experimental cell systems and TCGA datasets. Conclusions: Collectively, the prognostic framework incorporating zinc finger proteins demonstrates biomarker utility in lung adenocarcinoma survival prediction, while offering novel avenues for molecular target discovery in therapeutic strategies against this malignancy.